Across TCGA pan-cancer cohorts, ATG9A RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated ATG9A data layer compared with 8 for mutation status and 6 for mass-spec protein.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ATG9A RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATG9A expression acts as an unfavorable survival marker, although some lineages such as PAAD and THYM show a favorable association.
ACC, MESO, and LIHC are the cancer types where ATG9A RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.